Research Article | Open Access
Anna Sonja Müller, Klara Janjić, Gunpreet Oberoi, Manuela Pensch, Christoph Kurzmann, Andreas Moritz, Hermann Agis, "Deferoxamine but Not Dimethyloxalylglycine, L-Mimosine, or Cobalt Dichloride Can Interfere with the MTT Assay", BioMed Research International, vol. 2018, Article ID 5872865, 6 pages, 2018. https://doi.org/10.1155/2018/5872865
Deferoxamine but Not Dimethyloxalylglycine, L-Mimosine, or Cobalt Dichloride Can Interfere with the MTT Assay
Hypoxia mimetic agents (HMAs) have been shown to have a positive influence on cellular functions in a multitude of tissue regenerative strategies. Novel experimental approaches use biomaterials as carriers for controlled delivery of these HMAs. Here, the cytotoxic aspects of biocompatibility are of key relevance. The MTT assay is widely used to evaluate cytotoxicity and proliferation. Based on the implications from the proceeding research we hypothesized that specific HMAs such as deferoxamine at high concentrations can interfere with the MTT assay. Thus, the aim of this study was to test the repercussions of the HMAs dimethyloxalylglycine, deferoxamine, L-mimosine, and CoCl2 on the validity of the MTT assay. Murine MC3T3-E1 cells were cultured in serum-free alphaMEM and in alphaMEM supplemented with 10 % fetal bovine serum with the HMAs dimethyloxalylglycine, deferoxamine, L-mimosine, and CoCl2, respectively, at 3 mM-0.3 mM for 24 h (experimental groups). Cells without HMAs served as control (control groups). The same experiments were performed with medium and phosphate buffered saline (PBS) without cells. In all settings MTT solution was added to PBS-washed or unwashed culture plates for the last two hours of the incubation period. Then MTT solution was removed and dimethyl sulfoxide was added to dissolve the formazan crystals and absorption was measured. Our data show that the presence of deferoxamine can interfere with the MTT assay if not removed before the addition of MTT. This is particularly important when evaluating cell viability in setups where deferoxamine-loaded biomaterials are used.
Application of hypoxia-based strategies is a promising approach in the field of regenerative dentistry and for the treatment of systemic ischemic and inflammatory diseases [1, 2]. It is met with great interest as reflected by the increasing number of publications in this field over the last ten years . The use of hypoxia mimetic agents (HMAs) to simulate oxygen-deprived conditions is a common strategy applied in experimental settings . In particular, when the healing capacity is compromised, biomaterials releasing HMAs can stimulate regeneration [3–5]. Previous research has shown that stem cells derived from from apical papilla release proangiogenic molecules when exposed to CoCl2, inducing hypoxic conditions which in turn enhances pulp regeneration . HMAs furthermore increase intracellular HIF-1α levels, the regulator of cellular and developmental response to hypoxia, and thus lead to an increased VEGF production in dental pulp cells in vitro [7, 8]. Fracture healing in long bones and in mandibular distraction models in rodents improved when HMAs were applied for the activation of angiogenic factors during tissue repair [9–11]. Frequently used HMAs include dimethyloxalylglycine (DMOG), deferoxamine (DFO), L-mimosine (L-Mimo), and CoCl2 [1–3, 12, 13].
Various biomaterials are under development and evaluation for the release capacity of HMAs. These include collagen barrier membranes and bone substitute materials [12, 14–16]. The success of new scaffolds depends on the biocompatibility and release kinetics of these materials . One of the first steps in testing new materials for the property of being an “intrinsically biocompatible system” includes cytotoxicity testing along with other qualities . A well-established method to assess cytotoxicity and proliferation is the MTT assay which is based on the evaluation of the cellular metabolic activity as a measure of cell viability. The MTT assay is a colorimetric assay as oxidoreductase enzymes in viable cells convert the tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into dark blue formazan crystals. These formazan crystals are then dissolved with dimethyl sulfoxide (DMSO) causing purple coloration .
When evaluating the cytotoxicity of biomaterials which are loaded with HMAs and show a release of HMAs or when assessing the direct impact of HMAs it is important to choose a feasible assay. The MTT assay has been used for these purposes [3, 7, 8, 20]. When using this assay for evaluation of viability or proliferation, however, it is important to know whether the HMAs interfere with MTT assay leading to false positive or negative results. This is of importance, particularly when evaluating cells cultured on an HMA-loaded scaffold where HMAs cannot be removed for the assay. We found indications that the HMA DFO could interfere with MTT assay in previous studies [3, 8, 20]. However, currently no study on this issue is available although MTT assay has been used to measure viability of cells in response to DFO [7, 21]. We hypothesized that DMOG, L-Mimo, and CoCl2 do not interfere while DFO does interfere with the MTT assay. Thus, the aim of this study was to test the impact of the HMAs DMOG, DFO, L-Mimo, and CoCl2 on MTT assay.
2. Materials and Methods
2.1. Cell Culture and Plate Preparation
To assess the cell viability upon treatment with HMAs, MC3T3-E1 cells were seeded with alpha minimal essential medium (alphaMEM; Invitrogen Corporation, Carlsbad, CA, USA) supplemented with or without (serum free, SF) 10 % fetal calf serum (FCS; LifeTech, Vienna, Austria) and antibiotics in 96 well plates at 50,000 cells/cm2. The plates were incubated at 37 °C, 5 % CO2, and 95 % atmospheric moisture overnight. The HMAs DMOG, DFO, L-Mimo, and CoCl2 were then added at 3 mM, 1 mM, 0.3 mM, 0.1 mM, and 0.03 mM to cells with and without 10% FCS. The plates were again incubated at 37°C, 5% CO2, and 95% atmospheric moisture for 24 hours. In a separate set of experiments the cells were washed with PBS before the MTT assay was carried out. For the last 2 hours of incubation plates were subjected to the MTT assay.
To evaluate if HMAs can increase the absorbance in the MTT assay without cells, alphaMEM with and without 10% FCS was supplemented with the HMAs DMOG, DFO, L-Mimo, and CoCl2 at 3 mM, 1 mM, 0.3 mM, 0.1 mM, and 0.03 mM (experimental groups). Wells without HMA served as control (control groups). The plates were incubated at 37 °C, 5 % CO2, and 95 % atmospheric moisture for 24 hours and subjected to the MTT assay for the last 2 hours. In a separate set of experiments the wells were washed with PBS before the MTT assay was carried out. To reveal the impact of medium we performed the cell-free experiments also with PBS instead of alphaMEM. Here MTT assays were also performed with and without washing with PBS.
2.2. MTT Assay
The wells with and without cells were incubated with 1 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 2 h as previously described [14, 22–24]. MTT solution was discarded and 100 μL dimethyl sulfoxide (DMSO) was added per well. Formazan formation was quantified via photometric evaluation of the absorbance at 550 nm using the Synergy HTX Multi-Mode Reader (BioTek, Winooski, VT, USA).
2.3. Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics (IBM Corporation, Armonk, NY, USA), using the Kruskal-Wallis-test and post hoc Mann-Whitney-test. The level of significance was set at p < 0.05.
3. Results and Discussion
Utilizing the MTT assay, we first assessed the viability of MC3T3-E1 cells when exposed to four different HMAs DMOG, DFO, L-Mimo, and CoCl2 and compared the measured absorbance to the control, which was not exposed to any HMAs. We found that DMOG, L-Mimo, and CoCl2 did not substantially impair viability of MC3T3-E1 supplemented with 10% FCS at any HMA-concentration (Figure 1(a)(i)). However, CoCl2 induced a significant decrease at 3 mM with an absorbance of 0.180. The absorbance of the control was 1.352. For MC3T3-E1 cultured in serum-free medium (Figure 1(a)(ii)) we found similar results when treated with CoCl2 at 3 mM. The exposure to CoCl2 led to a significant decrease of viability, namely, to an absorbance of 0.205. Here the level of the control was 1.002. DMOG, L-Mimo, and CoCl2 did not impair cell viability significantly at the observed concentrations.
When performing these experiments without MC3T3-E1 cells, a pronounced increase in absorbance in the DFO treated group was observed (Figure 1(b)) while this was only observed as a nonsignificant trend in the presence of cells. The MTT assay with HMAs in the presence of alphaMEM with 10% FCS showed absorbance between 0.081 and 0.202 for DMOG, L-Mimo, and CoCl2 in all concentrations; thus all near to the level of the control which was 0.131. Only for DFO the absorbance values increased with the concentration reaching significant levels above 0.1 mM with a maximum at 3 mM. Here the absorbance was 0.694. The same was observed for the MTT assays carried out with HMAs in serum-free medium without cells (Figure 1(b)(ii)). Again, DFO at concentrations above 0.1 mM led to a significant increase in absorbance. The maximum absorbance for DFO was found at 3 mM with an absorbance of 0.517. The absorbance of the control was 0.167. DFO leading to such a pronounced increase in absorbance in the MTT assay in alphaMEM with and without FCS with no cells suggests that DFO reacts with a substance in the MTT assay and thus the absorbance cannot be used as a measure of cell viability in this case. We next evaluated what impact the removal of HMAs would have on the results of the MTT assay. Hence, we removed the HMAs by washing with PBS buffer before adding MTT. Here the evaluation of the optical densities showed different results. When applying MTT after washing away the HMAs the trend for an increase of absorbance by DFO was not visible, while a decrease of absorbance was observed for DMOG and CoCl2 at higher concentrations (Figure 2(a)). Thus, this strengthens our assumption that DFO might interfere with the MTT assay when not removed sufficiently. When performing the experiment without cells but only HMAs in alphaMEM with or without FCS including a washing step with PBS before applying the MTT assay, the absorbance levels remained similar to the levels of the control for all HMAs at all concentrations (Figure 2(b)). When the experiments were performed without MC3T3-E1 cells and no medium but only PBS, it showed no increase or decrease of absorbance compared to the control independent of adding a washing step (Figures 3(a) and 3(b)). Thus, the effect is medium dependent.
The findings of this paper are of clear relevance for researchers in the field of regenerative medicine focusing on hypoxia-based strategies. The MTT assay is a widespread tool in laboratories for cell viability testing and dose finding in vitro, especially in preliminary studies. Thus, potential misinterpreted results as is possible with DFO can have a major impact on follow-up studies. Especially studies on DFO-loaded materials such as bone substitutes, collagen matrices, or hydrogels need to be performed with a feasible test method [14, 21]. The impact on cell viability in the presence of high dosage of DFO might be underestimated based on the MTT results. In previous studies problems concerning possible interference of DFO with the MTT assay have been described. An increase in optical density is when human periodontal fibroblasts, human gingival fibroblasts, and dental pulp-derived cells were exposed to DFO at high concentrations (1 mM) that is why they excluded the data [3, 8]. Similar hurdles with the MTT assay were reported when murine bone marrow cultures were exposed to DFO . Again, high concentrations of DFO lead to a positive reading in the MTT assay even in the absence of cells. They also excluded the MTT assay data of cells treated with DFO .
A limitation of our study is that we performed the experiments with only one cell line. As the conversion rate of MTT can vary in various cell types, the magnitude of the interference with the viability assay results normalized to the untreated control might also be cell type-dependent. We also used one incubation time for the MTT solution as the incubation times chosen depend on the assay manufacturer and protocol used. We incubated the MC3T3-E1 cells with MTT for 2 hours based on ISO 10993-5:2009 . There, it is also stated that, depending on the cell type, different incubation times of up to 4 hours can be applied. As the same effect of the MTT assay was observed when various cells such as human dental pulp cells, human periodontal ligament cells, and murine monocytes were incubated with DFO, we do not believe that different cell types or longer incubation times would have made a major difference [3, 8, 20]. However, due to difference in the overall MTT conversion it is possible that the impact might vary with regard to the magnitude with different cell types.
Based on the results reported above we suggest that in addition to MTT other assays should be taken into consideration such as live-dead staining, resazurin based toxicity assays or bromodeoxyuridine (BrdU) incorporation assays to verify the results of the MTT assay when evaluating DFO-loaded scaffolds .
Future research should clarify the involved mechanism of the interference of DFO with the MTT assay.
The HMA DFO can interfere with the MTT assay leading to increased absorbance levels when not removed sufficiently. The absorbance increases with the DFO concentration suggesting that the impact of DFO-loaded biomaterials on cell viability can be underestimated when DFO cannot be removed before the assay.
The data used to support the findings of this study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors deny any conflicts of interest related to this study.
Our research was supported by the International Team for Implantology (ITI) Research Grant 1085_2015. Anna Sonja Müller received a research fellowship from the GEA Academy (Schrems, Austria). The authors acknowledge Franz Varga (Ludwig Boltzmann Institute of Osteology, Vienna, Austria) for providing MC3T3-E1 cells.
- A. S. Müller, K. Janjić, B. Lilaj, M. Edelmayer, and H. Agis, “Hypoxia-based strategies for regenerative dentistry—Views from the different dental fields,” Archives of Oral Biolog, vol. 81, pp. 121–130, 2017.
- P. Fraisl, J. Aragonés, and P. Carmeliet, “Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease,” Nature Reviews Drug Discovery, vol. 8, no. 2, pp. 139–152, 2009.
- H. Agis, G. Watzek, and R. Gruber, “Prolyl hydroxylase inhibitors increase the production of vascular endothelial growth factor by periodontal fibroblasts,” Journal of Periodontal Research, vol. 47, no. 2, pp. 165–173, 2012.
- D. Duscher, M. Januszyk, Z. N. Maan et al., “Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing,” Plastic and Reconstructive Surgery, vol. 139, no. 3, pp. 695–706, 2017.
- D. Duscher, E. Neofytou, V. W. Wong et al., “Transdermal deferoxamine prevents pressure-induced diabetic ulcers,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 112, no. 1, pp. 94–99, 2015.
- C. Yuan, P. Wang, L. Zhu et al., “Coculture of stem cells from apical papilla and human umbilical vein endothelial cell under hypoxia increases the formation of three-dimensional vessel-like structures in vitro,” Tissue Engineering Part A, vol. 21, no. 5-6, pp. 1163–1172, 2015.
- L. Jiang, W. W. Peng, and L. F. Li, “Effects of deferoxamine on the repair ability of dental pulp cells in vitro,” Journal of Endodontics, vol. 40, no. 8, pp. 1100–1104, 2014.
- H.-D. Müller, B. Cvikl, R. Gruber, G. Watzek, and H. Agis, “Prolyl hydroxylase inhibitors increase the production of vascular endothelial growth factor in dental pulp-derived cells,” Journal of Endodontics, vol. 38, no. 11, pp. 1498–1503, 2012.
- X. Shen, C. Wan, G. Ramaswamy et al., “Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice,” Journal of Orthopaedic Research, vol. 27, no. 10, pp. 1298–1305, 2009.
- A. Donneys, S. S. Deshpande, C. N. Tchanque-Fossuo et al., “Deferoxamine expedites consolidation during mandibular distraction osteogenesis,” Bone, vol. 55, no. 2, pp. 384–390, 2013.
- A. Donneys, A. S. Farberg, C. N. Tchanque-Fossuo, S. S. Deshpande, and S. R. Buchman, “Deferoxamine enhances the vascular response of bone regeneration in mandibular distraction osteogenesis,” Plastic and Reconstructive Surgery, vol. 129, no. 4, pp. 850–856, 2012.
- U. Kuchler, C. Keibl, A. Fügl et al., “Dimethyloxalylglycine lyophilized onto bone substitutes increase vessel area in rat calvarial defects,” Clinical Oral Implants Research, vol. 26, no. 5, pp. 485–491, 2015.
- H. Agis, L. Hueber, N. Pour Sadeghian, M. Pensch, and R. Gruber, “In vitro release kinetic of dimethyloxaloylglycine and l-mimosine from bovine bone mineral,” Archives of Oral Biolog, vol. 59, no. 10, pp. 1024–1031, 2014.
- D. Al-Habbal, K. Janjić, M. Edelmayer, A. Moritz, and H. Agis, “Collagen barrier membranes do not adsorb hypoxia mimetic activity-Activity of gingival fibroblasts cultured directly on collagen barrier membranes loaded with hypoxia mimetic agents,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 106, no. 2, pp. 874–879, 2018.
- O. Hamid, M. Pensch, and H. Agis, “Release kinetics of prolyl hydroxylase inhibitors from collagen barrier membranes,” Journal of Biomaterials Applications, vol. 29, no. 8, pp. 1059–1067, 2015.
- J. Caballé-Serrano, K. Sawada, R. J. Miron, D. D. Bosshardt, D. Buser, and R. Gruber, “Collagen barrier membranes adsorb growth factors liberated from autogenous bone chips,” Clinical Oral Implants Research, vol. 28, no. 2, pp. 236–241, 2017.
- D. F. Williams, “On the mechanisms of biocompatibility,” Biomaterials, vol. 29, no. 20, pp. 2941–2953, 2008.
- D. F. Williams, “There is no such thing as a biocompatible material,” Biomaterials, vol. 35, no. 38, pp. 10009–10014, 2014.
- T. L. Riss, R. A. Moravec, A. L. Niles et al., “Cell Viability Assays,” in Assay Guidance Manual. Eli Lilly Company and the National Center for Advancing Translational Sciences, G. S. Coussens, N. P. Nelson, H. Arkin et al., Eds., Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004.
- P. Vinzenz, S. Schröckmair, R. Gruber, and H. Agis, “Bone substitute materials supplemented with prolyl hydroxylase inhibitors decrease osteoclastogenesis in vitro,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 103, no. 6, pp. 1198–1203, 2015.
- M. Edelmayer, D. Al-Habbal, M. Pensch, K. Janjic, and H. Agis, “Effect of prolyl hydroxylase inhibitor-loaded collagen barrier membranes on osteoclastogenesis and osteoblastogenesis,” Journal of Biomaterials Applications, vol. 31, no. 10, pp. 1370–1379, 2017.
- N. Schlueter, A. Lussi, C. Ganss, and R. Gruber, “L929 fibroblast bioassay on the in vitro toxicity of SnCl2, H3PO4, Clearfil SE primer and combinations thereof,” Swiss Dental Journal, vol. 126, no. 6, pp. 566–572, 2016.
- B. Kandler, P. Maitz, M. B. Fischer, G. Watzek, and R. Gruber, “Platelets can neutralize hydrogen peroxide in an acute toxicity model with cells involved in granulation tissue formation,” Bone, vol. 36, no. 4, pp. 671–677, 2005.
- B. Cvikl, A. Lussi, and R. Gruber, “The in vitro impact of toothpaste extracts on cell viability,” European Journal of Oral Sciences, vol. 123, no. 3, pp. 179–185, 2015.
- ISO 10993-5:2009. Biological evaluation of medical devices.
Copyright © 2018 Anna Sonja Müller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.